Orbimed Advisors Llc Sells 115,844 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 115,844 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the transaction, the director owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. This trade represents a 4.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Wednesday, May 27th, Orbimed Advisors Llc sold 101 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total value of $4,493.49.
• On Monday, May 11th, Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58.
• On Friday, May 8th, Orbimed Advisors Llc sold 59,767 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total value of $2,664,412.86.
• On Thursday, May 7th, Orbimed Advisors Llc sold 48,546 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.61, for a total value of $2,165,637.06.
• On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.52, for a total value of $131,244.96.
• On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.68, for a total transaction of $2,341,097.96.
• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total transaction of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14.

Sionna Therapeutics Stock Performance

Shares of NASDAQ:SION opened at $43.99 on Friday. The firm has a 50 day moving average of $39.85 and a 200-day moving average of $39.53. The stock has a market capitalization of $1.99 billion, a PE ratio of -22.79 and a beta of 1.33. Sionna Therapeutics, Inc. has a 12 month low of $16.38 and a 12 month high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, research analysts predict that Sionna Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Sionna Therapeutics during the 4th quarter valued at $36,000. Russell Investments Group Ltd. acquired a new position in Sionna Therapeutics in the 3rd quarter worth about $30,000. Balyasny Asset Management L.P. acquired a new position in Sionna Therapeutics in the 4th quarter worth about $58,000. BNP Paribas Financial Markets bought a new position in Sionna Therapeutics in the second quarter valued at about $31,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Sionna Therapeutics in the fourth quarter valued at about $89,000.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on SION shares. Citizens Jmp restated a “market outperform” rating and set a $63.00 target price on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Stifel Nicolaus lifted their price target on Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, May 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. Wedbush initiated coverage on Sionna Therapeutics in a research report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price objective for the company. Finally, JonesTrading raised their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Sionna Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.22.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.